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Abstract
Background: In late 2002, the health authorities of Mozambique implemented sulphadoxine-pyrimethamine
(SP)/amodiaquine (AQ) as first-line treatment against uncomplicated falciparum malaria. In 2004, this has been
altered to SP/artesunate in line with WHO recommendations of using Artemisinin Combination Therapies
(ACTs), despite the fact that all the neighbouring countries have abandoned SP-drug combinations due to high
levels of SP drug resistance. In the study area, one year prior to the change to SP/AQ, SP alone was used to treat
uncomplicated malaria cases. The study described here investigated the immediate impact of the change to SP on
the frequency of SP and CQ resistance-related haplotypes in the Plasmodium falciparum genes Pfdhfr, Pfdhps and
Pfcrt before and a year after the introduction of SP.
Methods: Samples were collected during two cross sectional surveys in early 2002 and 2003 involving 796 and
692 children one year or older and adults randomly selected living in Maciana, an area located in Manhiça district,
Southern Mozambique. Out of these, 171 and 173 P. falciparum positive samples were randomly selected to
measure the frequency of resistance- related haplotypes in Pfdhfr, Pfdhps and Pfcrt based on results obtained by
nested PCR followed by sequence-specific oligonucleotide probe (SSOP)-ELISA.
Results: The frequency of the SP-resistance associated Pfdhps double mutant (SGEAA) haplotype increased
significantly from 14% to 35% (P < 0.001), while the triple mutant Pfdhfr haplotype (CIRNI) remained high and
only changed marginally from 46% to 53% (P = 0.405) after one year with SP as first-line treatment in the study
area. Conversely, the combined Pfdhfr/Pfdhps quintuple mutant haplotype increased from 8% to 26% (P = 0.005).
The frequency of the chloroquine resistance associated Pfcrt-CVIET haplotype was above 90% in both years.
Conclusion: These retrospective findings add to the general concern on the lifespan of the combination of SP/
artesunate in Mozambique. The high frequency of quintuple Pfdhfr/Pfdhps haplotypes found here as early as 2002
most likely cause ideal conditions for the development of artesunate tolerance in the P. falciparum populations and
may even endanger the sensitivity to the second-line drug, Coartem®.
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Background
Large scale prevalence of Plasmodium falciparum chloro-
quine (CQ), amodiaquine (AQ) and sulphadoxine/
pyrimethamine (SP) resistance has forced countries with
endemic malaria to change to the artemisinin combina-
tion therapies (ACTs) as first-line treatment against
uncomplicated malaria. The ACT drugs, currently being
implemented in sub-Saharan Africa combine various
artemisinin analogues with novel drugs (lumefantrine,
i.e. Coartem®) or with already widely used drugs such as
AQ and SP. ACTs are highly efficacious and are likely to
decrease the rate of development of resistance, and thus
expand the useful lifetime of the drugs [1]. Artemisinin
derivates are acting and are eliminated rapidly after treat-
ment and the development of resistance to ACTs will
probably depend on the already existing background level
of resistance to the partner drugs in the parasite popula-
tion, as it has been observed in areas with high levels of
resistance to SP and AQ [2,3]. Currently, SP combined
with artesunate (ART) is the first-line treatment policy in
few African countries, such as Mozambique (from 2004)
and Northern Sudan [4,5]. In Mozambique, prior to
adoption of the ACT strategy, the combination of AQ and
SP as the first-line treatment was implemented in late
2002 following reports of high levels of chloroquine (CQ)
resistance [6]. However, one year prior to this change, SP
alone was used to treat uncomplicated malaria cases in the
study area. Additionally, SP has recently been used in pro-
grammes examining the efficacy of intermittent presump-
tive treatment (IPT) intervention in pregnant women and
infants in Mozambique [7,8].
The prevalence of combinations of single nucleotide pol-
ymorphisms (SNP) in the P. falciparum dihydrofolate
reductase (Pfdhfr) and dihydropteroate synthetase
(Pfdhps) genes have been correlated with resistance to SP
in vivo [9,10]. In Africa, the Pfdhfr  triple mutation,
N51I+C59R+S108N, with wildtype at codons 50 (C50)
and 164 (I164), is combined into a highly prevalent and
resistant haplotype, CIRNI. For Pfdhps the double muta-
tion, A437G + K540E, with wildtype at codons 436
(S436) 581 (A581) and 613 (A613) are combined into
the resistant haplotype SGEAA. The combination of the
two; CIRNI-SGEAA, have been suggested as a molecular
marker of in vivo resistance [10]. However, recent studies
have questioned the association between this combina-
tion of molecular markers and drug resistance in vivo by
showing that differences in responses to SP treatment was
a consequence of acquired immunity rather than parasite
factors [11,12].
Resistance to both CQ and AQ is mainly associated with a
single K76T mutation in the P. falciparum chloroquine
resistance transporter gene (Pfcrt), but are probably
involving mutations in the P. falciparum multi-drug resist-
ance (Pfmdr1) gene as well [13,14]. Three main haplo-
types in codons 72–76 of the Pfcrt gene exist, namely the
wild type CVMNK and the CQ resistant haplotypes, CVIET
and SVMNT [15], where CVIET is by far the most domi-
nant mutant haplotype in Africa while SVMNT haplotypes
has only been observed sporadically [16].
The objective of this study was to determine the frequency
of Pfdhfr, Pfdhps and Pfcrt resistance related haplotypes in
P. falciparum isolates collected before and a year after SP
was introduced as first-line treatment, as replacement for
CQ in the study area. Moreover, since Mozambique was
implementing a treatment policy with SP in combination
with artesunate as first line treatment of uncomplicated
malaria, the findings of this study in addition to recent
studies [17,18] is providing crucial baseline information
of the level of drug resistance related haplotypes present
in the parasite population prior to the adoption of the
ACT strategy in the country.
Methods
Study population and samples
The study was conducted in Maciana, a village located in
Manhiça district Southern Mozambique with 14.496
inhabitants [19]. The climate is characterized by a warm
and wet season from November to April and a dry and
cold season from May to October. The area is hyper-
endemic for malaria and the transmission is perennial
with marked seasonality and the majority of cases occur
during the rainy season reaching a peak in during Febru-
ary and May. Ninety percent of all infections are caused by
P. falciparum, but P. malariae and  P. ovale are also
observed. The population is mainly made up of farmers
growing maize and beans and do have access to one
health post which serves only outpatients [19]. Samples
for analysis of molecular markers of drug resistance were
collected during two cross sectional surveys involving 796
and 692 children one year or older and adults randomly
selected from the Manhiça demographic surveillance sys-
tem. The first cross-sectional study was conducted before
the introduction of SP as first-line treatment in the study
area, from December 2001 to January 2002 (survey 1);
and the second, from January to February 2003 (survey 2).
Finger prick blood samples were obtained for thick and
thin blood smears and for filter paper blood spots.
Ethical clearance for the study was provided by the
National Institute of Health, Ministry of Health of
Mozambique Ethical Committee. The Danish National
Committee on Biomedical Research Ethics commented
on the proposal and recommended the study. Written
informed consent was obtained from adults and the par-
ents/guardians of the children before enrolment.Malaria Journal 2008, 7:115 http://www.malariajournal.com/content/7/1/115
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DNA extraction and detection of polymorphisms in of 
Pfdhfr, Pfdhps and the Pfcrt
For practical reasons, 171 and 173 samples from cross sec-
tional survey 1 and 2, respectively, were selected ran-
domly for the analyses of polymorphisms in Pfdhfr, Pfdhps
and Pfcrt. DNA extraction from bloodspots and nested
PCR followed by the sequence specific oligonucleotide
probe (SSOP)-ELISA was performed and analysed as pre-
viously described [20] using SSOPs targeting SNPs in Pfd-
hfr at c50/51 (CI/CN), c59 (C/R), c108 (S/N/T) and c164
(I/L) and in Pfdhps at c436/437 (AA/AG/SA/SG/FG) c540
(K/E), c581 (A/G) and c613 (A/S). The resulting single
nucleotide polymorphisms (SNPs) were constructed into
haplotypes. For Pfcrt, SSOPs targeting the haplotypes
CVMNK, CVIET and SVMNT was used [20].
Statistics
All statistical analyses were performed using SigmaStat
software package version 3.0.1 and SPSS statistical pack-
age version 15.0. For the statistical analyses of the charac-
teristics of the individuals sampled during the cross-
sectional studies, the differences between groups were
assessed using the Chi-square test for proportions and the
Student t-test for continuous normal distributed variables.
Frequencies of mutations between groups were compared
using the Chi-square or Fisher exact test. In addition, a
logistic regression model was used to compare haplotype
distributions obtained in the two cross-sectional surveys
while adjusting for the potential confounding effects of P.
falciparum density and age.
Results
A total of 244 and 192 samples were P. falciparum positive
by microscopy in cross-sectional survey 1 and 2, respec-
tively out of which 171 and 173 samples were chosen ran-
domly for the genotyping analysis. The populations in the
two surveys differed in respect to age and parasite density:
In survey 2, the median age was significantly lower (P =
0.013) while the parasite density was significantly higher
(P < 0.001) compared to survey 1 (Table 1). Only Pfdhfr
wildtypes at c164 was found, while for Pfdhps, only
wildtypes were observed at c518 and c613.
A significant increase in the frequency of Pfdhps double
mutant haplotype, SGEAA from 13.5% to 34.8% over a
year was found (χ2 = 12.24, P < 0.001), mainly decreasing
the frequency of Pfdhps  wildtypes SAKAA/AAKAA from
80.8% to 64.3% (χ2 = 5.893, P = 0.015; Figure 1A). For
Pfdhfr, there was only a marginal difference between the
two surveys with a frequency of the triple mutant haplo-
type, CIRNI at 46.5% and 53.2% in survey 1 and 2, respec-
tively (χ2 = 0.70, P = 0.405; Figure 1B). When combining
the two loci, the frequency of parasites carrying the highly
resistant  Pfdhfr/Pfdhps  quintuple haplotype increased
from 8.0% to 25.8% (χ2 = 7.78, P = 0.005) between survey
1 and 2. The change in frequency was not at the expense
of the wildtype Pfdhfr/Pfdhps  haplotype, CNCSI-SAKAA
that remained stable at 11%, but rather on the double
mutant haplotypes, where the CNRNI-SAKAA accounted
for a decrease from 26.7% to 18.0% (χ2 = 1.32, P = 0.250)
and the triple mutant haplotype, mainly the CIRNI-
SAKAA that decreased from 37.3% to 27.0% (χ2 = 1.57, P
= 0.210) (Figure 2). Logistic regression analysis revealed
that all of the above mentioned statistical results (with
regards to significance) persisted after appropriate adjust-
ment for P. falciparum density and age.
The prevalence of single nucleotide polymorphisms in
Pfdhfr  and Pfdhps  is shown in Table 2. In Pfdhfr, only
minor differences can be seen between the two cross sec-
tional surveys where a strong trend for a decrease in the
prevalence of the 108S wildtype is apparent (from 49.6%
to 38.0%, χ2 = 3.06, P = 0.080). For Pfdhps, as expected
from the combined haplotype data, both a decrease of the
436/437SA wildtype (from 85.7% to 71.0%, χ2 = 7.18, P
= 0.007) and an increase in the mutant 436/437SG
mutant type (from 56.4% to 68.5%, χ2 = 3.46, P = 0.063)
is evident. Furthermore, the prevalence of the 540 K
wildtype is decreasing significantly from 92.1% to 71.6%
(χ2 = 16.66, P < 0.001).
Major differences in prevalence of infections with Pfdhps
and combined Pfdhfr/Pfdhps mutations were found when
comparing different age groups (i.e. 1–5, 6–14 and > 14
years), however only in the second survey (Table 3): The
Table 1: Characteristics of the randomly selected samples for the analysis of molecular markers of drug resistance from cross sectional 
surveys in December 2001 (Cross1) and January 2003 (Cross 2)
Cross1 
N = 171
Cross2 
N = 173
P-value
Median age (years) (25–75% percentile) 14
(8.0–27.8)
11
(6.0–23.5)
0.013
Gender, male (%) 43.3 45.7 0.772
Median P. falciparum density, parasites/μl (25–75% percentile) 125
(63–423)
332
(84–2242)
< 0.001
Donors with temperature >37.5°C (%) 4.1 4.6 0.982
P-values: Mann-Whitney Rank Sum Test or χ2-tests comparisons between the two cross sectional surveys.Malaria Journal 2008, 7:115 http://www.malariajournal.com/content/7/1/115
Page 4 of 7
(page number not for citation purposes)
prevalence of quintuple mutant haplotype was signifi-
cantly higher in children under fives compared to the
older age groups (χ2 = 6.04, P = 0.049) and a strong ten-
dency for a higher frequency of Pfdhps  double mutant
haplotypes in children under fives compared to the older
groups was seen (χ2 = 5.33, P = 0.069).
The samples analysis of the Pfcrt  gene showed almost
exclusively the occurrence of the mutant haplotype CVIET
in both years (92.8% in survey 1 and 95.3% in survey 2;
χ2 = 0.74, P = 0.389), while the remaining samples were
the wild type CVMNK haplotype.
Discussion
In late 2002, Mozambique changed the treatment policy
from CQ to SP/AQ against uncomplicated malaria. Prior
to this change, the present study implemented SP alone as
first line treatment in the study area and as a possible con-
sequence, the study observed a rapid increase in frequency
of double SGEAA-Pfdhps  and quintuple CIRNI-SGEAA-
Pfdhfr/Pfdhps mutant haplotypes at the community level
just a year after. Prior to the introduction of SP the con-
sumption of this drug was very low in the study area [19].
However, since the study did not measure the actual use
of SP outside the health services, the study cannot rule out
alternative explanations such as consumption of other
antifolate drugs and for instance changes in migration.
The triple mutant CIRNI-Pfdhfr  haplotype, was highly
prevalent prior to the change (46.5%), also observed in
2000 in Matola (50.9%), a peri-urban area within Maputo
province [21]. Similarly, Raman et al observed a remarka-
ble increase of the triple mutant haplotype in 13 sentinel
sites stratified into three zones in Maputo province
between 1999 and 2003, almost reaching 100% in 2003
Table 2: The prevalence of single nucleotide polymorphisms 
(SNP) at codon 51, 59 and 108 of Pfdhfr and codon 436/437 and 
540 of Pfdhps in the two cross sectional surveys
Pfdhfr codon Cross1 Cross2 P
N( % ) N( % )
51 N 43 32.3 33 27.8 0.169
I 49 36.8 58 46.0 0.507
Mixed (N/I) 41 30.8 33 26.2
59 C 16 12.7 14 11.0 0.853
R 66 52.4 69 54.3 0.828
Mixed (C/R) 44 87.3 44 34.6
108 S 14 11.0 8 6.2 0.080
N 64 50.4 80 62.0 0.249
Mixed (S/N) 49 38.6 41 31.8
Pfdhps codon N (%) N (%)
436/437 AA 3 2.4 1 0.8 0.746
SA 50 39.7 37 29.8 0.007
SG 15 11.9 35 28.2 0.063
Mixed
AA/SA 2 1.6 1 0.8
SA/SG 56 44.4 45 36.3
A A / S A / S G 00 54 . 0
540 K 80 63.5 73 54.5 < 0.001
E 10 7.9 38 28.4 0.117
Mixed (K/E) 36 28.6 23 17.2
The data are given as total numbers and as percentages and including 
genotype infections where the identification of SNP/haplotypes for a 
few samples were not complete. Mixed: Prevalence of infections with 
mixed SNP for each codon. P: P-values of χ2-tests of prevalence 
comparisons between the two cross sectional surveys where the 
prevalence of infections of each SNP including mixed infections are 
set against prevalence of infections without the particular SNP.
The Frequency of Pfdhps (A) and Pfdhfr (B) haplotypes in  December 2001 (black bars) and January 2003 (red bars) in  Manhiça district Figure 1
The Frequency of Pfdhps (A) and Pfdhfr (B) haplo-
types in December 2001 (black bars) and January 
2003 (red bars) in Manhiça district. After removing the 
PCR negatives and the samples with mixed haplotype infec-
tions (where a major haplotype could not be determined), 
for Pfdhps, N = 104 and 115 and for Pfdhfr, N = 99 and 109 
from survey 1 and 2, respectively.
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[18], while Fernandes et al found 93% of the triple mutant
haplotype in samples from children with uncomplicated
malaria attending a Health Centre in Maputo city of
Mozambique in 2004 [17].
This high frequency of Pfdhfr mutations before the actual
implementation of SP/AQ as first-line drug in Mozam-
bique may be due to the use of other chemically related
drugs such as co-trimoxazole, which is commonly used in
the study area for treating bacterial infections and as a pre-
ventive measure in HIV/AIDS patients (Dr Yunuss Assane,
MoH, personal communication). While not shown in
vivo, in vitro cross-resistance has been reported between
co-trimoxazole and SP components [22]. More impor-
tantly, as suggested by Raman et al, since neighbouring
KwaZulu-Natal province in South Africa implemented SP
as early as 1988, the high frequency before SP implemen-
tation in Mozambique may be caused by SP drug pressure
from the border region [18].
In the present study, the most notable change was the
increase of the double mutant Pfdhps SGEAA haplotype
from 13.5% to 34.8% over only one year. In the study by
Raman et al, the frequency of the double mutant haplo-
type peaked in 2001 at 19–25% in all three zones fol-
lowed by a remarkable and significant decrease in 2003
and 2004 to less than 10% [18], in sharp contrast to the
findings by Fernandes et al, where the frequency was 51%
in their 2004 study [17], presumably due to differences in
sampling where the latter study was done on samples
from symptomatic children attending a health centre.
Such a difference in frequency in symptomatic cases ver-
sus asymptomatic carriers has likewise been shown in a
study performed in Tanzania [23].
In the second survey of this study, the quintuple Pfdhfr/
Pfdhps  haplotype was more frequent in children under
fives compared to the older age groups. Similar findings,
but rather for Pfdhfr haplotypes alone was seen by Raman
et al [18] and is most likely due to a stronger survival
advantage of the mutant parasites in the younger age
groups due to the more frequent treatments this group
receive. It also pinpoints a potential pitfall when measur-
ing prevalence of molecular markers of drug resistance in
under-fives when these data are extrapolated to cover the
population as a whole.
The high prevalence of these mutant haplotypes in the
area as early as 2001 along with the findings by Fernandes
et al [17] and Raman et al [18], questions the current effi-
cacy of the first-line antimalarial drug in Mozambique, a
combination of ART and SP. Results from in vivo study car-
ried out in the same area in 2001 have described a rela-
tively high adequate clinical response to SP after 14 days
of follow-up at 82.7% [6]. However, the levels of treat-
ment failures and RI and RII parasitological resistance
increased when follow-up was extended to 28 days, indi-
cating a decline in the efficacy of SP as early as 2001. Most
likely, initially ART/SP was an efficient treatment against
uncomplicated malaria in Mozambique, however the risk
of clinical treatment failures could be expected to appear
within a short span of years, since the benefits of ACT
Table 3: The prevalence of triple mutations in Pfdhfr, double 
mutations in Pfdhps and quintuple mutations in Pfdhfr/Pfdhps in 
the two cross sectional surveys according to age
Pfdhfr triple MT Pfdhps double MT Pfdhfr and Pfdhps
quintuple MT
Age
(years)
Cross1 Cross2 Cross1 Cross2 Cross1 Cross2
1–5 4/12
(33.3)
16/24
(66.7)
2/12
(16.7)
11/21
(52.4)
1/10
(10.0)
8/16
(50.0)
6–14 20/43
(46.5)
24/43
(55.8)
7/46
(15.2)
17/45
(37.8)
1/31
(3.2)
8/36
(22.2)
>14 22/44
(50.0)
18/42
(42.9)
7/46
(15.2)
12/49
(24.5)
4/34
(11.8)
7/37
(18.9)
P = 0.591 0.160 0.991 0.069 0.434 0.049
The donors are divided into 1–5 years, 6–14 years and above 14 years 
of age. Actual numbers of infections with Pfdhfr triple, Pfdhps double 
and Pfdhfr/Pfdhps quintuple mutations are shown out of total with the 
percentage of total in brackets. P: P-value of χ2-tests.
The Frequency of combined Pfdhfr/dhps haplotypes in  December 2001 (dark bars) and January 2003 (red bars) in  Manhiça district in Manhiça district Figure 2
The Frequency of combined Pfdhfr/dhps haplotypes in 
December 2001 (dark bars) and January 2003 (red 
bars) in Manhiça district in Manhiça district. After 
removing the PCR negatives and the samples with mixed 
haplotype infections (where a major haplotype could not be 
determined), N = 75 and 89 samples from survey 1 and 2, 
respectively.
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combinations are diminished by the inclusion of an inef-
fective partner drug, such as SP, where ART/SP may be
equivalent to ART monotherapy. Despite that mutations
in Pfdhfr/Pfdhps may not directly cause clinical ART/SP
treatment failures, a high prevalence of SP resistance-
related mutations may rather indicate a risk of emerging
tolerance to ART endangering the whole ACT strategy in
the region. Close and frequent monitoring of the efficacy
of the drug combination should be performed as well as
formulation of a strategy for alternative first line treat-
ment.
Conclusion
The high frequency of quintuple Pfdhfr/Pfdhps haplotypes
found here as early as 2002 most likely cause ideal condi-
tions for the development of ART tolerance in the P. falci-
parum populations and may even endanger the sensitivity
to the second-line drug, Coartem.
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